Fisher Asset Management LLC bought a new stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) during the third quarter, HoldingsChannel reports. The institutional investor bought 105,999 shares of the company’s stock, valued at approximately $10,093,000.
Other large investors have also recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Rhythm Pharmaceuticals during the second quarter worth $683,601,000. Primecap Management Co. CA purchased a new stake in shares of Rhythm Pharmaceuticals in the second quarter valued at $351,838,000. Pictet Asset Management Holding SA lifted its position in shares of Rhythm Pharmaceuticals by 2.0% in the third quarter. Pictet Asset Management Holding SA now owns 976,487 shares of the company’s stock valued at $93,019,000 after acquiring an additional 18,702 shares in the last quarter. Jupiter Topco LLC acquired a new stake in shares of Rhythm Pharmaceuticals during the second quarter valued at $102,752,000. Finally, Siren L.L.C. boosted its stake in shares of Rhythm Pharmaceuticals by 45.1% during the first quarter. Siren L.L.C. now owns 725,511 shares of the company’s stock valued at $63,098,000 after acquiring an additional 225,536 shares during the last quarter.
Rhythm Pharmaceuticals Stock Performance
RYTM stock opened at $115.02 on Monday. The company has a 50 day moving average price of $96.88 and a two-hundred day moving average price of $97.44. The stock has a market capitalization of $7.97 billion, a P/E ratio of -39.66 and a beta of 2.17. Rhythm Pharmaceuticals, Inc. has a one year low of $74.50 and a one year high of $122.20.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on RYTM shares. Citigroup reiterated a “market outperform” rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, August 5th. Citizens Jmp boosted their target price on shares of Rhythm Pharmaceuticals from $160.00 to $166.00 and gave the company a “market outperform” rating in a research note on Wednesday, November 4th. Oppenheimer restated a “market perform” rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, November 4th. Deutsche Bank initiated coverage on shares of Rhythm Pharmaceuticals in a report on Friday, August 28th. They issued a “hold” rating and a $120.00 target price on the stock. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Rhythm Pharmaceuticals in a research note on Wednesday, November 4th. Eighteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $142.00.
Read Our Latest Research Report on Rhythm Pharmaceuticals
Insiders Place Their Bets
In related news, CEO David P. Meeker sold 50,000 shares of the company’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $102.67, for a total value of $5,133,500.00. Following the completion of the transaction, the chief executive officer directly owned 239,258 shares in the company, valued at approximately $24,564,618.86. This represents a 17.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Hunter C. Smith sold 62,774 shares of the stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $105.46, for a total value of $6,620,146.04. Following the transaction, the chief financial officer owned 114,024 shares in the company, valued at $12,024,971.04. This trade represents a 35.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.90% of the stock is owned by insiders.
Rhythm Pharmaceuticals Profile
Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance. Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies.
Read More
- Five stocks we like better than Rhythm Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding RYTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report).
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
